IL240206A0 - Preparations containing amorphous sulfasalazine and their uses - Google Patents

Preparations containing amorphous sulfasalazine and their uses

Info

Publication number
IL240206A0
IL240206A0 IL240206A IL24020615A IL240206A0 IL 240206 A0 IL240206 A0 IL 240206A0 IL 240206 A IL240206 A IL 240206A IL 24020615 A IL24020615 A IL 24020615A IL 240206 A0 IL240206 A0 IL 240206A0
Authority
IL
Israel
Prior art keywords
compositions
amorphous sulfasalazine
sulfasalazine
amorphous
Prior art date
Application number
IL240206A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glialogix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glialogix Inc filed Critical Glialogix Inc
Publication of IL240206A0 publication Critical patent/IL240206A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL240206A 2013-02-01 2015-07-29 Preparations containing amorphous sulfasalazine and their uses IL240206A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759933P 2013-02-01 2013-02-01
US201361780340P 2013-03-13 2013-03-13
PCT/US2014/014290 WO2014121137A2 (en) 2013-02-01 2014-01-31 Compositions and methods for the treatment of neurodegenerative and other diseases

Publications (1)

Publication Number Publication Date
IL240206A0 true IL240206A0 (en) 2015-09-24

Family

ID=50382538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240206A IL240206A0 (en) 2013-02-01 2015-07-29 Preparations containing amorphous sulfasalazine and their uses

Country Status (10)

Country Link
US (5) US9597339B2 (enExample)
EP (1) EP2950797B1 (enExample)
JP (2) JP6328146B2 (enExample)
KR (1) KR20150139830A (enExample)
CN (1) CN105163735B (enExample)
AU (2) AU2014212109B2 (enExample)
CA (1) CA2899032A1 (enExample)
ES (1) ES2752021T3 (enExample)
IL (1) IL240206A0 (enExample)
WO (1) WO2014121137A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752021T3 (es) * 2013-02-01 2020-04-02 Glialogix Inc Composiciones y métodos para el tratamiento de enfermedades neurodegenerativas y otras enfermedades
KR102364840B1 (ko) * 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
US20160199393A1 (en) * 2015-01-08 2016-07-14 China Medical University Methods of treating brain ischemia or hypoxia
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
CN109414507A (zh) * 2016-04-26 2019-03-01 美国圣路易斯大学 用于预防和治疗神经退行性疾病的高度选择性腺苷a3受体亚型激动剂
TW201818933A (zh) * 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
US20230210871A1 (en) * 2017-10-12 2023-07-06 The Limited Company Research And Development Company "Medbiopharm" Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products
US11033506B2 (en) 2017-11-21 2021-06-15 Sekisui Chemical Co., Ltd. External skin preparation comprising a core-shell structure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
JPH10506406A (ja) 1994-09-29 1998-06-23 アンダリス、リミテッド 治療用ビヒクルとしての噴霧乾燥させた微細粒子
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ITMI962356A1 (it) 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
ES2289823T3 (es) 1998-08-25 2008-02-01 Advanced Inhalation Research, Inc. Formulaciones proteicas estables secadas por atomizacion.
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
KR100417623B1 (ko) * 2000-03-28 2004-02-05 주식회사 뉴로테크 뇌질환 예방 및 치료용 조성물
CA2307278A1 (en) 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP1824564A4 (en) 2004-10-27 2009-09-16 Uab Research Foundation METHOD FOR TREATING GLIOM
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
US20070053869A1 (en) 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
BRPI0707684B1 (pt) 2006-02-02 2021-10-13 Novartis Ag Uso de 40-o-(2-hidroxietil)-rapamicina para fabricar medicamento para tratar distúrbios mediados pelo complexo de esclerose tuberosa
US7964585B2 (en) 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
ES2953390T3 (es) 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20110014282A1 (en) * 2008-02-28 2011-01-20 De Vasconcelos Teofilo Cardoso Pharmaceutical composition for poorly soluble drugs
PL2113254T3 (pl) * 2008-04-28 2013-01-31 Txcell Kompozycje do leczenia autoimmunologicznego stanu zapalnego
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2013115965A1 (en) 2012-01-31 2013-08-08 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
ES2752021T3 (es) * 2013-02-01 2020-04-02 Glialogix Inc Composiciones y métodos para el tratamiento de enfermedades neurodegenerativas y otras enfermedades
ES3041833T3 (en) 2013-12-31 2025-11-14 Ascendia Pharmaceuticals Llc Pharmaceutical compositions for poorly water-soluble compounds

Also Published As

Publication number Publication date
US9597339B2 (en) 2017-03-21
US20140221321A1 (en) 2014-08-07
WO2014121137A3 (en) 2014-11-27
US9918997B2 (en) 2018-03-20
US9980978B2 (en) 2018-05-29
AU2014212109B2 (en) 2018-05-31
US20170079990A1 (en) 2017-03-23
JP2018123159A (ja) 2018-08-09
JP6328146B2 (ja) 2018-05-23
US20190015431A1 (en) 2019-01-17
AU2018222921A1 (en) 2018-09-20
CN105163735B (zh) 2018-12-11
US9974798B2 (en) 2018-05-22
AU2014212109A1 (en) 2015-08-06
CA2899032A1 (en) 2014-08-07
US20170165279A1 (en) 2017-06-15
JP2016507526A (ja) 2016-03-10
US20170079991A1 (en) 2017-03-23
WO2014121137A2 (en) 2014-08-07
EP2950797A2 (en) 2015-12-09
US10398713B2 (en) 2019-09-03
EP2950797B1 (en) 2019-09-11
ES2752021T3 (es) 2020-04-02
KR20150139830A (ko) 2015-12-14
CN105163735A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
GB2520795B (en) Compositions and methods
GB2535911B (en) Strigolactone formulations and uses thereof
IL245504B (en) Preparations containing dextromethorphan and bupropion or similar substances and their uses
IL241225A0 (en) Plant-based compositions and their uses
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
IL244850A0 (en) Stabilized epinaconazole preparations, and their uses
EP2989240A4 (en) INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
GB201308072D0 (en) Compositions and methods
GB201317286D0 (en) Composition and Use
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
GB201321693D0 (en) Composition and uses thereof
SG11201509448WA (en) Creamer compositions and uses thereof
IL240206A0 (en) Preparations containing amorphous sulfasalazine and their uses
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en) Compositions and methods
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
SG11201508192WA (en) Polymer compositions and nonwoven compositions prepared therefrom
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201318151D0 (en) Composition and device
GB201308242D0 (en) Compositions and uses thereof
IL246134A0 (en) Gel preparations containing testosterone and their uses
GB201301022D0 (en) Composition and uses thereof
GB201322617D0 (en) Methods and compositions